|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts显示文摘AIM: To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts. METHODS: All consecutive patients with histologically confirmed, metastatic PAC and World Health Organiza-tion performance status (PS) ≤ 2 received FOLFIRI-1 [irinotecan 180 mg/m2 on day 1 and leucovorin 400 mg/m2 followed by 5-fluorouracil (5-FU) 400 mg/m2 bolus, then 5-FU 2400 mg/m2 as a 46-h infusion, biweekly] or FOLFIRI-3 (irinotecan 100 mg/m2 on day 1 and leucovorin 400 mg/m2, then 5-FU 2400 mg/m2 as a 46-h infusion and irinotecan 100 mg/m2 repeated on day 3, biweekly) after failure of gemcitabine and platinum-based chemotherapies as a systematic policy in two institutions between January 2005 and May 2010. Tumor response, time to progression (TTP), overall survival rate (OS) and grade 3-4 toxicities were retrospectively studied. Subgroup analyses were performed to search for prognostic factors. RESULTS: Sixty-three patients (52.4% male, median age 59 years) were analyzed. Among them, 42.9% were PS 0, 38.1% were PS 1 and 19.0% were PS 2. Fifty one patients (81.0%) had liver metastases. Before the FOLFIRI regimen, patients had received 1 line (n = 19), 2 lines (n = 39) or 3 lines (n = 5) of chemotherapy. Median TTP obtained with the line before FOLFIRI was 3.9 mo (95% CI: 3.4-5.3 mo). A total of 480 cycles was completed (median: 6 cycles, range: 1-51 cycles). The main reason for discontinuing FOLFIRI was tumor progression (90.3%). Tumor control was achieved in 25 patients (39.7%) (partial response: n = 5, stable disease: n = 20) with FOLFIRI. Median TTP was 3.0 mo (95% CI: 2.1-3.9 mo) and median OS was 6.6 mo (95% CI: 5.3-8.1 mo). Dose adaptation was required in 36 patients (57.1%). Fifteen patients (23.8%) had grade 3-4 toxicities, mainly hematological (n = 11) or digestive (n = 4). Febrile neutropenia occurred in 3 patients. There was no toxic death. PS 2 was significantly associated with poor TTP [hazard ratio (HR): 16.036, P < 0.0001] and OS (HR: 4.003, P = 0.004). CONCLUSION: The FOLFIRI regimen had an acceptable toxicity and an interesting efficacy in our study, limited to patients in good condition (PS 0-1). | Cindy Neuzillet Olivia Hentic Benot Rousseau Vinciane Rebours Léla Bengrine-Lefèvre Franck Bonnetain Philippe Lévy Eric Raymond Philippe Ruszniewski Christophe Louvet Pascal Hammel | 2012 | World Journal of Gastroenterology2012，18，33： | 3 |
| 2 | Natural History of Intraductal Papillary Mucinous Tumors of the Pancreas: Actuarial Risk of Malignancy显示文摘 | Philippe Lévy Vincent Jouannaud Dermot O’Toole Anne Couvelard Marie Pierre Vullierme Laurent Palazzo Alain Aubert Philippe Ponsot Alain Sauvanet Frédérique Maire Olivia Hentic Pascal Hammel Philippe Ruszniewski | 2006 | Clinical Gastroenterology and Hepatology2006，，4： | 2 |
| 3 | The long term risk of malignancy in patients with branch duct intraductal papillary mucinous neoplasms of the pancreas显示文摘 | Wafaa Khannoussi Marie Pierre Vullierme Vinciane Rebours Frédérique Maire Olivia Hentic Alain Aubert Alain Sauvanet Safi Dokmak Anne Couvelard Pascal Hammel Philippe Ruszniewski Philippe Lévy | 2012 | Pancreatology2012，，3： | 1 |
| 4 | FOLFIRI regi- men: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neu- roendoerine carcinomas grade 3 显示文摘 | Hentic O Hammel P Couvelard A | 2012 | Endocr Relat Cane- er2012，19，6： | 1 |
| 5 | FOLFIRI regimen assecond-/third-line chemotherapy in patients with advanced pan-creatic adenocarcinoma refractory to gemcitabine and platinumsalts : A retrospective series of 70 patients 显示文摘 | Neuzillet C Hentic 0 Rousseau B | 2011 | J Clin Oncol2011，29，： | 1 |
| 6 | Does tobacco influence the natural history of autoimmune pancreatitis?显示文摘 | Frédérique Maire Vinciane Rebours Marie Pierre Vullierme Anne Couvelard Philippe Levy Olivia Hentic Maxime Palazzo Pascal Hammel Philippe Ruszniewski | 2014 | Pancreatology2014，，： | 1 |
| 7 | Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors?显示文摘 | Frédérique Maire Pascal Hammel Reza Kianmanesh Olivia Hentic Anne Couvelard Vinciane Rebours Magaly Zappa Eric Raymond Alain Sauvanet Christophe Louvet Philippe Lévy Jacques Belghiti Philippe Ruszniewski | 2009 | Surgery2009，，1： | 1 |
| 8 | Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors : a safe approach for radical resection 显示文摘 | Kianmanesh R Sauvanet A Hentic O | 2008 | Ann Surg2008，247，4： | 1 |
| 9 | Immunoglobulin G4 Immunostaining of Gastric, Duodenal, or Colonic Biopsies Is Not Helpful for the Diagnosis of Autoimmune Pancreatitis显示文摘 | Vinciane Rebours Yann Le Baleur Dominique Cazals–Hatem Carmen Stefanescu Olivia Hentic Frédérique Maire Yoram Bouhnik Pierre Bedossa Pascal Hammel Philippe Ruszniewski Philippe Lévy Anne Couvelard | 2012 | Clinical Gastroenterology and Hepatology2012，，1： | 1 |
| 10 | Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma显示文摘 | Hedia Brixi-Benmansour Jean-Louis Jouve Emmanuel Mitry Franck Bonnetain Bruno Landi Olivia Hentic Laurent Bedenne Guillaume Cadiot | 2011 | Digestive and Liver Disease2011，，： | 1 |
| 11 | Are the Causes Similar for Benign and Severe Forms of Acute Pancreatitis?显示文摘 | Hentic O Levy P Hammel P | 2003 | Gastroenterol Clin Biol2003，27，4： | 1 |
| 12 | Are the causes similar for benign and severe forms of acute pancreatitis显示文摘 | Hentic O Levy P Hammel P | 2003 | Gastroenterol Clin Biol2003，27，4： | 1 |
| 13 | FOLFIRI regimen as second-/third-line chemotherapy in patients with ad- vanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: a retrospective series of 70 patients 显示文摘 | NEUZILLET C HENTIC O ROUSSEAU B | 2011 | J Clin Oncol2011，，： | 1 |
| 14 | Smoking and the course of recurrent acute and chronic alcoholic pancrcatitis: a dose - depend- ent relationship显示文摘 | Rebours V Vullierme MP Hentic O | 2012 | Pancreas2012，41，8： | 1 |
| 15 | Gemcitabine in elderly patients with advanced pancreatic cancer显示文摘AIM:To assess feasibility,tolerability and efficacy of gemcitabine-based chemotherapy in patients≥75 years old with advanced pancreatic cancer.METHODS:All consecutive patients≥75 years old with advanced pancreatic adenocarcinoma were included in this retrospective study.Necessary criteria to receive chemotherapy were:performance status 0-2,adequate biological parameters and no serious comorbidities.Other patients received best supportive care(BSC).RESULTS:Thirty-eight patients(53%women,median age 78 years,range 75-84)with pancreatic cancer(metastatic:n=20,locally advanced:n=18)were studied.Among them,30(79%)were able to receivechemotherapy[median number:9 infusions(1-45)].Six patients(23%)had at least one episode of grade 3 neutropenia and one patient developed a grade 3 hemolytic-uremic syndrome.No toxic death occurred.Three patients(11%)had a partial tumor response,13(46%)had a stable disease and 12(43%)had a tumor progression.Median survival was 9.1 mo(metastatic:6.9 mo,locally advanced:11.4 mo).CONCLUSION:Tolerance and efficacy of gemcitabinebased chemotherapy is acceptable in elderly patients in good condition,with similar results to younger patients. | Olivia Hentic Vinciane Rebours Philippe Lévy Philippe Ruszniewski Pascal Hammel Magaly Zappa Chantal Dreyer Eric Raymond | 2011 | World Journal of Gastroenterology2011，17，30： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员